Advertisement

Current Osteoporosis Reports

, Volume 14, Issue 5, pp 178–186 | Cite as

Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives

  • Cemre Robinson
  • Michael T. Collins
  • Alison M. BoyceEmail author
Epidemiology and Pathophysiology (J Cauley and B Dawson-Hughes, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Epidemiology and Pathophysiology

Abstract

Fibrous dysplasia (FD) is an uncommon and debilitating skeletal disorder resulting in fractures, deformity, functional impairment, and pain. It arises from post-zygotic somatic activating mutations in GNAS, in the cAMP-regulating transcript α-subunit, Gsα. Constitutive Gs signaling results in activation of adenylyl cyclase and dysregulated cAMP production. In the skeleton, this leads to the development of FD lesions with abnormal bone matrix, trabeculae, and collagen, produced by undifferentiated mesenchymal cells. FD may occur in isolation or in combination with extraskeletal manifestations, including hyperfunctioning endocrinopathies and café-au-lait macules, termed McCune-Albright syndrome (MAS). This review summarizes current clinical and translational perspectives in FD/MAS, with an emphasis on FD pathogenesis, natural history, pre-clinical and clinical investigation, and future directions.

Keywords

Fibrous dysplasia McCune-Albright syndrome GNAS gene Gsα FGF23 

Notes

Compliance with Ethical Standards

Conflict of Interest

Cemre Robinson, Michael T Collins, and Alison M Boyce declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human subjects performed by any of the authors.

With regard to the authors’ research cited in this paper, all institutional and national guidelines for the care and use of laboratory animals were followed.

Funding

This research was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lichtenstein L. Polyostotic fibrous dysplasia. Arch Surg. 1938;36:874–98.CrossRefGoogle Scholar
  2. 2.
    Weinstein LS et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Turan S, Bastepe M. GNAS spectrum of disorders. Curr Osteoporos Rep. 2015;13(3):146–58.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 1990;348(6297):125–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Riminucci M. et al. Fibrous dysplasia as a stem cell disease. J Bone Miner Res, 2006. 21 Suppl 2: p. P125-31.Google Scholar
  6. 6.
    Piersanti S et al. Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res. 2010;25(5):1103–16.PubMedGoogle Scholar
  7. 7.
    Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet. 1986;29(4):321–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Endo M et al. Monozygotic twins discordant for the major signs of McCune-Albright syndrome. Am J Med Genet. 1991;41(2):216–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Lemli L. Fibrous dysplasia of bone. Report of female monozygotic twins with and without the McCune-Albright syndrome. J Pediatr. 1977;91(6):947–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Peleg R, Treister-Goltzman Y. Images in clinical medicine: McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99(4):1105–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Bianco P et al. Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest. 1998;101(8):1737–44.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Riminucci M et al. The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks. J Pathol. 1999;187(2):249–58.CrossRefPubMedGoogle Scholar
  13. 13.
    Collins MT, Riminucci M, Bianco P. Fibrous dysplasia. In: Rosen C, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Washington, DC: American Society of Bone and Mineral Research: p. 2013: 786–793.Google Scholar
  14. 14.
    Hart ES et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007;22(9):1468–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Ippolito E et al. Radiographic classification of coronal plane femoral deformities in polyostotic fibrous dysplasia. Clin Orthop Relat Res. 2014;472(5):1558–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Leet AI et al. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res. 2004;19(4):571–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Leet AI et al. Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis. J Bone Joint Surg Am. 2004;86-A(3):531–7.PubMedGoogle Scholar
  18. 18.•
    Boyce AM, Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome. In GeneReviews(R), Pagon RA, et al, Editors. 1993, University of Washington, Seattle: Seattle WA. This review contains specific diagnostic and treatment algorithms compiled from the highest quality evidenced-based literature and expert opinion currently available.Google Scholar
  19. 19.••
    Amit M et al. Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia—a meta-analysis. PLoS One. 2011;6(9):e25179. This meta-analysis establishes that prophylactic optic nerve decompression is contraindicated in patients with FD involving the optic canals without evidence of objective vision loss.Google Scholar
  20. 20.
    Frisch CD et al. Fibrous dysplasia of the temporal bone: a review of 66 cases. Laryngoscope. 2015;125(6):1438–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7 Suppl 1:S4.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Boyce AM et al. Characterization and management of testicular pathology in McCune-Albright syndrome. J Clin Endocrinol Metab. 2012;97(9):E1782–90.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Celi FS et al. The role of type 1 and type 2 5′-deiodinase in the pathophysiology of the 3,5,3′-triiodothyronine toxicosis of McCune-Albright syndrome. J Clin Endocrinol Metab. 2008;93(6):2383–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Boyce AM, Bhattacharyya N, Collins MT. Fibrous dysplasia and fibroblast growth factor-23 regulation. Curr Osteoporos Rep. 2013;11(2):65–71.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Brown RJ, Kelly MH, Collins MT. Cushing syndrome in the McCune-Albright syndrome. J Clin Endocrinol Metab. 2010;95(4):1508–15.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.••
    Boyce AM et al. Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess. J Clin Endocrinol Metab. 2013;98(1):E126–34. This paper demonstrates that early diagnosis and treatment of growth hormone excess in FD/MAS prevents long-term craniofacial morbidity.Google Scholar
  27. 27.
    Leet AI et al. The correlation of specific orthopaedic features of polyostotic fibrous dysplasia with functional outcome scores in children. J Bone Joint Surg Am. 2006;88(4):818–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Ruggieri P et al. Malignancies in fibrous dysplasia. Cancer. 1994;73(5):1411–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Collins MT et al. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab. 2003;88(9):4413–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Tanabeu Y et al. Breast cancer in a patient with McCune-Albright syndrome. Breast Cancer. 1998;5(2):175–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Huston TL, Simmons RM. Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Breast J. 2004;10(5):440–2.CrossRefPubMedGoogle Scholar
  32. 32.
    Wu J et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92ra66.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Gaujoux S et al. Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99(1):E97–101.CrossRefPubMedGoogle Scholar
  34. 34.
    Parvanescu A et al. Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: GNAS-activating mutations in pancreatic carcinogenesis. JAMA Surg. 2014;149(8):858–62.CrossRefPubMedGoogle Scholar
  35. 35.
    Riminucci M et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kuznetsov SA et al. Age-dependent demise of GNAS-mutated skeletal stem cells and “normalization” of fibrous dysplasia of bone. J Bone Miner Res. 2008;23(11):1731–40.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Bhattacharyya N et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012;27(5):1132–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Leet AI, Collins MT. Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. J Child Orthop. 2007;1(1):3–17.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Paul SM et al. Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia. Bone. 2014;60:41–7.CrossRefPubMedGoogle Scholar
  40. 40.••
    Leet AI et al. Bone-grafting in polyostotic fibrous dysplasia. J Bone Joint Surg Am. 2016;98(3):211–9. This study demonstrates that the common surgical practice of bone grafting is frequently ineffective in patients with FD, particularly children.Google Scholar
  41. 41.
    Stanton RP, Ippolito E, Springfield D, Lindaman L, Wientroub S, Leet A. The surgical management of fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;24 Suppl 1:S1.CrossRefGoogle Scholar
  42. 42.
    Mancini F et al. Scoliosis and spine involvement in fibrous dysplasia of bone. Eur Spine J. 2009;18(2):196–202.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gabbay JS et al. Fibrous dysplasia of the zygomaticomaxillary region: outcomes of surgical intervention. Plast Reconstr Surg. 2013;131(6):1329–38.CrossRefPubMedGoogle Scholar
  44. 44.
    Lee J, Fitzgibbon E, Chen Y, Kim H, Lustig L, Akintoye S, Collins M, Kaban L. Clinical guidelines for the management of craniofacial fibrous dysplasia. 2012. 24 Suppl 1:S2(7): p. Suppl 1:S2.Google Scholar
  45. 45.
    Lee JS et al. Normal vision despite narrowing of the optic canal in fibrous dysplasia. N Engl J Med. 2002;347(21):1670–6.CrossRefPubMedGoogle Scholar
  46. 46.•
    Boyce AM et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab. 2014;99(11):4133–40. This study reports the first randomized controlled trial in FD, demonstrating that oral alendronate is ineffective in improving FD-related pain or the radiographic appearance of FD lesions.Google Scholar
  47. 47.
    Chapurlat RD et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone. 2004;35(1):235–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994;343(8903):953–4.CrossRefPubMedGoogle Scholar
  49. 49.
    Plotkin H et al. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88(10):4569–75.CrossRefPubMedGoogle Scholar
  50. 50.
    Kelly MH, Brillante B, Collins MT. Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. Osteoporos Int. 2008;19(1):57–63.CrossRefPubMedGoogle Scholar
  51. 51.
    Salenave S. et al. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab, 2014: p. jc20133826.Google Scholar
  52. 52.
    Tessaris D et al. Thyroid abnormalities in children and adolescents with McCune-Albright syndrome. Horm Res Paediatr. 2012;78(3):151–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Hsiao EC et al. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci U S A. 2008;105(4):1209–14.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Hsiao EC et al. Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation. J Bone Miner Res. 2010;25(3):584–93.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Saggio I et al. Constitutive expression of Gsalpha(R201C) in mice produces a heritable, direct replica of human fibrous dysplasia bone pathology and demonstrates its natural history. J Bone Miner Res. 2014;29(11):2357–68.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Bianco P et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19(1):35–42.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Kagami H et al. The use of bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for alveolar bone tissue engineering: basic science to clinical translation. Tissue Eng Part B Rev. 2014;20(3):229–32.CrossRefPubMedGoogle Scholar
  58. 58.
    Robey PG et al. Generation of clinical grade human bone marrow stromal cells for use in bone regeneration. Bone. 2015;70:87–92.CrossRefPubMedGoogle Scholar
  59. 59.
    Kim N, Cho SG. New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation. Int J Stem Cells. 2015;8(1):54–68.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Bhattacharyya N et al. A high throughput screening assay system for the identification of small molecule inhibitors of gsp. PLoS One. 2014;9(3), e90766.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Dempster DW et al. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin Ther. 2012;34(3):521–36.CrossRefPubMedGoogle Scholar
  62. 62.
    Prolia [package insert]. Thousand Oaks, CA., 2010. Amgen, Inc.Google Scholar
  63. 63.
    Xgeva [package insert]. Thousand Oaks, CA., 2010. Amgen, Inc.Google Scholar
  64. 64.
    Xu SF et al. Denosumab and giant cell tumour of bone—a review and future management considerations. Curr Oncol. 2013;20(5):e442–7.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Singh AS, Chawla NS, Chawla SP. Giant-cell tumor of bone: treatment options and role of denosumab. Biologics. 2015;9:69–74.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Thomas D et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.CrossRefPubMedGoogle Scholar
  67. 67.
    Wang HD et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014;99(3):891–7.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment. Joint Bone Spine. 2014;81(6):549–50.CrossRefPubMedGoogle Scholar
  69. 69.
    Boyce AM et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462–70.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Gossai N et al. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078–80.CrossRefPubMedGoogle Scholar
  71. 71.
    Grasemann C et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab. 2013;98(8):3121–6.CrossRefPubMedGoogle Scholar
  72. 72.
    Setsu N et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34(1):118–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2016

Authors and Affiliations

  • Cemre Robinson
    • 1
  • Michael T. Collins
    • 1
  • Alison M. Boyce
    • 1
    • 2
    • 3
    Email author
  1. 1.Section on Skeletal Disorders and Mineral Homeostasis, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial ResearchNational Institutes of HealthBethesdaUSA
  2. 2.Division of Endocrinology and DiabetesChildren’s National Health SystemWashingtonUSA
  3. 3.Bone Health Program, Division of Orthopaedics and Sports MedicineChildren’s National Health SystemWashingtonUSA

Personalised recommendations